Compare SCLX & BCHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | BCHT |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 36.6M |
| IPO Year | 2020 | 2016 |
| Metric | SCLX | BCHT |
|---|---|---|
| Price | $4.90 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 36.4K | ★ 66.3K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,253,000.00 | $17,626,366.00 |
| Revenue This Year | $122.52 | $13.42 |
| Revenue Next Year | $186.30 | $61.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.26 |
| 52 Week Low | $4.20 | $1.14 |
| 52 Week High | $34.27 | $2.48 |
| Indicator | SCLX | BCHT |
|---|---|---|
| Relative Strength Index (RSI) | 27.24 | 69.08 |
| Support Level | $4.20 | $1.46 |
| Resistance Level | $7.77 | $1.79 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 5.93 | 96.00 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.